Vir Total Assets vs Retained Earnings Analysis

VIR Stock

USD 7.86 0.24 3.15%

Vir Biotechnology financial indicator trend analysis is much more than just breaking down Vir Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vir Biotechnology is a good investment. Please check the relationship between Vir Biotechnology Total Assets and its Retained Earnings accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vir Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.

Total Assets vs Retained Earnings

Total Assets vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vir Biotechnology Total Assets account and Retained Earnings. At this time, the significance of the direction appears to have very week relationship.

The correlation between Vir Biotechnology's Total Assets and Retained Earnings is 0.25. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Vir Biotechnology, assuming nothing else is changed. The correlation between historical values of Vir Biotechnology's Total Assets and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Vir Biotechnology are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Assets i.e., Vir Biotechnology's Total Assets and Retained Earnings go up and down completely randomly.

Correlation Coefficient

0.25

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Assets

Total assets refers to the total amount of Vir Biotechnology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vir Biotechnology books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Vir Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vir Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vir Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.As of 11/29/2024, Enterprise Value is likely to grow to about 1.8 B, though Tax Provision is likely to grow to (55.4 M).

	2021	2022	2023	2024 (projected)
Interest Income	439K	28.1M	82.4M	86.5M
Net Interest Income	439K	28.1M	82.4M	86.5M

Interest Income Net Interest Income

Vir Biotechnology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.92	0.96	0.99	0.85	0.89	0.98	-0.63	0.25	0.73	0.83	0.92	-0.73	0.25	0.94	-0.35	0.84	0.95	-0.51	0.87	0.98	0.93	0.69	0.99	0.89	1.0
Other Current Liab	0.92		0.98	0.88	0.68	0.73	0.85	-0.8	0.43	0.64	0.92	0.75	-0.9	0.27	0.9	-0.16	0.68	0.8	-0.38	0.71	0.84	0.77	0.8	0.88	0.74	0.94
Total Current Liabilities	0.96	0.98		0.93	0.74	0.79	0.91	-0.7	0.37	0.73	0.86	0.85	-0.85	0.23	0.89	-0.22	0.75	0.87	-0.43	0.78	0.9	0.84	0.79	0.93	0.81	0.97
Total Stockholder Equity	0.99	0.88	0.93		0.86	0.91	0.99	-0.59	0.14	0.73	0.79	0.93	-0.65	0.29	0.93	-0.37	0.9	0.97	-0.62	0.92	0.99	0.96	0.59	1.0	0.89	0.99
Other Liab	0.85	0.68	0.74	0.86		0.98	0.88	-0.32	0.05	0.77	0.61	0.8	-0.35	0.09	0.85	-0.77	0.76	0.9	-0.56	0.91	0.88	0.84	0.46	0.86	0.98	0.84
Net Tangible Assets	0.89	0.73	0.79	0.91	0.98		0.92	-0.35	0.02	0.77	0.65	0.88	-0.4	0.15	0.85	-0.72	0.83	0.96	-0.62	0.95	0.92	0.9	0.48	0.91	0.98	0.89
Property Plant And Equipment Net	0.98	0.85	0.91	0.99	0.88	0.92		-0.56	0.14	0.73	0.78	0.93	-0.62	0.29	0.93	-0.41	0.87	0.96	-0.54	0.9	1.0	0.97	0.62	0.99	0.9	0.98
Net Debt	-0.63	-0.8	-0.7	-0.59	-0.32	-0.35	-0.56		-0.46	-0.11	-0.93	-0.33	0.85	-0.49	-0.73	-0.2	-0.4	-0.44	0.14	-0.36	-0.56	-0.5	-0.64	-0.59	-0.33	-0.67
Retained Earnings	0.25	0.43	0.37	0.14	0.05	0.02	0.14	-0.46		0.03	0.37	0.04	-0.69	-0.52	0.31	0.19	-0.26	-0.03	0.53	-0.2	0.12	-0.09	0.74	0.14	0.18	0.28
Accounts Payable	0.73	0.64	0.73	0.73	0.77	0.77	0.73	-0.11	0.03		0.37	0.78	-0.39	-0.02	0.63	-0.5	0.68	0.77	-0.51	0.75	0.73	0.69	0.47	0.73	0.8	0.72
Cash	0.83	0.92	0.86	0.79	0.61	0.65	0.78	-0.93	0.37	0.37		0.59	-0.84	0.47	0.87	-0.12	0.6	0.71	-0.31	0.64	0.77	0.73	0.72	0.79	0.62	0.85
Non Current Assets Total	0.92	0.75	0.85	0.93	0.8	0.88	0.93	-0.33	0.04	0.78	0.59		-0.51	0.17	0.76	-0.4	0.86	0.95	-0.56	0.89	0.93	0.93	0.55	0.93	0.87	0.9
Non Currrent Assets Other	-0.73	-0.9	-0.85	-0.65	-0.35	-0.4	-0.62	0.85	-0.69	-0.39	-0.84	-0.51		-0.13	-0.72	-0.21	-0.38	-0.5	0.05	-0.35	-0.6	-0.49	-0.86	-0.65	-0.45	-0.75
Other Assets	0.25	0.27	0.23	0.29	0.09	0.15	0.29	-0.49	-0.52	-0.02	0.47	0.17	-0.13		0.27	0.16	0.5	0.32	-0.49	0.39	0.3	0.45	-0.11	0.29	-0.01	0.25
Cash And Short Term Investments	0.94	0.9	0.89	0.93	0.85	0.85	0.93	-0.73	0.31	0.63	0.87	0.76	-0.72	0.27		-0.35	0.77	0.86	-0.47	0.8	0.93	0.86	0.64	0.93	0.84	0.96
Good Will	-0.35	-0.16	-0.22	-0.37	-0.77	-0.72	-0.41	-0.2	0.19	-0.5	-0.12	-0.4	-0.21	0.16	-0.35		-0.34	-0.52	0.36	-0.61	-0.41	-0.41	-0.08	-0.37	-0.72	-0.33
Common Stock Total Equity	0.84	0.68	0.75	0.9	0.76	0.83	0.87	-0.4	-0.26	0.68	0.6	0.86	-0.38	0.5	0.77	-0.34		0.92	-0.86	0.94	0.88	0.93	0.22	0.9	0.73	0.83
Common Stock Shares Outstanding	0.95	0.8	0.87	0.97	0.9	0.96	0.96	-0.44	-0.03	0.77	0.71	0.95	-0.5	0.32	0.86	-0.52	0.92		-0.68	0.98	0.97	0.98	0.5	0.97	0.92	0.94
Non Current Liabilities Total	-0.51	-0.38	-0.43	-0.62	-0.56	-0.62	-0.54	0.14	0.53	-0.51	-0.31	-0.56	0.05	-0.49	-0.47	0.36	-0.86	-0.68		-0.78	-0.55	-0.65	0.21	-0.62	-0.48	-0.5
Capital Surpluse	0.87	0.71	0.78	0.92	0.91	0.95	0.9	-0.36	-0.2	0.75	0.64	0.89	-0.35	0.39	0.8	-0.61	0.94	0.98	-0.78		0.91	0.95	0.35	0.92	0.89	0.86
Other Current Assets	0.98	0.84	0.9	0.99	0.88	0.92	1.0	-0.56	0.12	0.73	0.77	0.93	-0.6	0.3	0.93	-0.41	0.88	0.97	-0.55	0.91		0.97	0.6	0.99	0.9	0.97
Other Stockholder Equity	0.93	0.77	0.84	0.96	0.84	0.9	0.97	-0.5	-0.09	0.69	0.73	0.93	-0.49	0.45	0.86	-0.41	0.93	0.98	-0.65	0.95	0.97		0.47	0.96	0.84	0.92
Total Liab	0.69	0.8	0.79	0.59	0.46	0.48	0.62	-0.64	0.74	0.47	0.72	0.55	-0.86	-0.11	0.64	-0.08	0.22	0.5	0.21	0.35	0.6	0.47		0.59	0.59	0.71
Net Invested Capital	0.99	0.88	0.93	1.0	0.86	0.91	0.99	-0.59	0.14	0.73	0.79	0.93	-0.65	0.29	0.93	-0.37	0.9	0.97	-0.62	0.92	0.99	0.96	0.59		0.89	0.99
Property Plant And Equipment Gross	0.89	0.74	0.81	0.89	0.98	0.98	0.9	-0.33	0.18	0.8	0.62	0.87	-0.45	-0.01	0.84	-0.72	0.73	0.92	-0.48	0.89	0.9	0.84	0.59	0.89		0.88
Total Current Assets	1.0	0.94	0.97	0.99	0.84	0.89	0.98	-0.67	0.28	0.72	0.85	0.9	-0.75	0.25	0.96	-0.33	0.83	0.94	-0.5	0.86	0.97	0.92	0.71	0.99	0.88

Click cells to compare fundamentals

Vir Biotechnology Account Relationship Matchups

Vir Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	512.1M	918.8M	2.0B	2.8B	1.9B	1.3B
Other Current Liab	46.9M	83.9M	226.4M	469.7M	91.2M	147.1M
Total Current Liabilities	59.2M	99.1M	341.2M	511.0M	175.4M	194.6M
Total Stockholder Equity	423.9M	716.9M	1.4B	2.1B	1.6B	941.7M
Other Liab	28.9M	36.3M	47.6M	89.3M	102.6M	107.8M
Net Tangible Assets	371.3M	666.1M	1.4B	2.0B	2.3B	2.4B
Property Plant And Equipment Net	16.3M	79.9M	130.1M	188.2M	167.2M	94.1M
Net Debt	(109.1M)	(370.0M)	(214.3M)	(720.7M)	(130.3M)	(136.8M)
Retained Earnings	(368.5M)	(667.2M)	(138.6M)	377.2M	(237.8M)	(249.7M)
Accounts Payable	5.9M	5.1M	6.5M	6.4M	6.3M	6.5M
Cash	109.3M	436.6M	347.8M	848.6M	254.8M	350.9M
Non Current Assets Total	109.1M	146.4M	391.4M	283.0M	330.8M	219.0M
Non Currrent Assets Other	15.8M	15.7M	(87.1M)	(228.5M)	18.9M	19.8M
Other Assets	9.2M	77.7M	9.8M	21.2M	1.0	0.95
Cash And Short Term Investments	383.4M	736.9M	708.1M	2.4B	1.5B	949.0M
Common Stock Shares Outstanding	107.6M	119.2M	133.4M	134.8M	134.1M	129.3M
Short Term Investments	274.1M	300.3M	360.3M	1.6B	1.3B	1.3B
Liabilities And Stockholders Equity	512.1M	918.8M	2.0B	2.8B	1.9B	1.3B
Non Current Liabilities Total	28.9M	102.8M	181.2M	213.1M	153.4M	150.7M
Capital Surpluse	14.7M	793.1M	1.4B	1.6B	1.8B	1.9B
Capital Lease Obligations	237K	70.4M	133.6M	123.8M	124.5M	71.1M
Other Current Assets	13.4M	53.1M	81.6M	117.0M	106.8M	60.5M
Other Stockholder Equity	281.0M	1.4B	1.6B	1.7B	1.8B	1.1B
Total Liab	88.1M	201.9M	522.4M	724.1M	328.8M	401.8M
Net Invested Capital	423.9M	716.9M	1.4B	2.1B	1.6B	941.7M
Property Plant And Equipment Gross	16.3M	17.9M	130.1M	188.2M	201.1M	211.2M
Total Current Assets	403.0M	772.4M	1.6B	2.5B	1.6B	1.1B
Accumulated Other Comprehensive Income	(601K)	(1.3M)	(1.1M)	(9.1M)	(815K)	(855.8K)
Non Current Liabilities Other	12.9M	95.8M	25.4M	32.8M	40.2M	35.9M
Net Working Capital	343.8M	673.3M	1.2B	2.0B	1.4B	929.9M
Short Term Debt	237K	3.6M	3.9M	4.1M	12.9M	13.5M
Intangible Assets	35.7M	33.8M	33.3M	32.8M	22.6M	26.4M
Property Plant Equipment	16.3M	17.9M	130.1M	188.2M	216.4M	227.2M
Current Deferred Revenue	6.2M	6.5M	98.2M	15.5M	64.9M	36.7M

Pair Trading with Vir Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving against Vir Stock

0.43	ZTS	Zoetis Inc	Pair Corr
0.33	HLN	Haleon plc	Pair Corr

The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.

The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Vir Stock Analysis

When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC